{"id":"W4376114963","doi":"10.51731/cjht.2023.640","title":"Olaparib (Lynparza)","year":2023,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Olaparib; Reimbursement; Medicine; Oncology; Germline; Internal medicine; BRCA mutation; Adjuvant; Drug; Human Epidermal Growth Factor Receptor 2; Chemotherapy; Breast cancer; Gynecology; Cancer; Pharmacology; Political science; Genetics; Biology","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006678274,0.00009387394,0.0003457009,0.00106247,0.0001704974,0.00001639172,0.0001888292,0.0001261705,0.00007550715],"category_scores_gemma":[0.0003780923,0.00008124526,0.00008192173,0.0008251901,0.0002001972,0.0000707672,0.00000969853,0.0004393972,0.00009037116],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005098539,"about_ca_system_score_gemma":0.003766723,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008094752,"about_ca_topic_score_gemma":0.0006535354,"domain_scores_codex":[0.9987502,0.00002908314,0.0004768774,0.0001020686,0.0001778887,0.0004639329],"domain_scores_gemma":[0.9991394,0.00004337782,0.0002688854,0.0002404024,0.0001649623,0.0001429635],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00004505704,0.00001757205,0.01589192,0.0001851661,0.00009038772,0.0009140553,0.0005040953,0.00002687297,0.000501799,0.003033862,0.2887954,0.6899939],"study_design_scores_gemma":[0.001228725,0.0006619479,0.02084637,0.000509803,0.00001201229,0.00101896,0.002716031,0.00001716361,0.002489106,0.008081855,0.9622969,0.0001211244],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"commentary","genre_gemma":"empirical","genre_scores_codex":[0.4335095,0.07129177,0.0004483238,0.487746,0.002141807,0.0005783745,0.00005129909,0.001050958,0.003181935],"genre_scores_gemma":[0.9961129,0.001338623,0.0004654581,0.001754208,0.00003182628,0.000007151451,0.000003869233,0.00001759444,0.0002683364],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.6898727,"threshold_uncertainty_score":0.6682006,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06684353766478728,"score_gpt":0.3530063722913855,"score_spread":0.2861628346265982,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}